Introduction
Approximately 21 500 new cases of gastric cancer are diagnosed annually in the United States, and 10 880 patients are expected to succumb to this disease in 2008 [1] ; the prognosis of these patients is poor (with a 5-year survival rate of 20% for all stages combined) and is primarily related to the extent of disease at presentation. The most frequent site of recurrence following R0 resection for gastric cancer is the peritoneum [2, 3] , resulting most likely from the intraperitoneal presence of free cancer cells shed from the serosal surface of the primary tumor [4] . Moreover, operative manipulation could result in dissemination of cancer cells, and this may be particularly true when suboptimal (D0) lymphadenectomy is performed. Cytologic examination of peritoneal washings at laparotomy has been used to detect these cells and predict the risk of recurrent disease [5, 6] . A close association between positive cytology and poor survival rate has been demonstrated [5, 7] . However, intraperitoneal recurrence has been observed even in patients with negative cytology [8] , suggesting a lack of sensitivity of conventional cytologic examination.
Reverse transcriptase polymerase chain reaction (RT-PCR) has been used to identify the presence of carcinoembryonic antigen (CEA) [9, 10] and cytokeratin 20 (CK20) mRNA in peritoneal washings of patients with gastric cancer [11, 12] . In one Japanese study, which demonstrated 80% sensitivity and 94% specifi city rates of RT-PCR for CEA mRNA, the survival of CEA mRNA-positive patients was poor and approached that of cytology-positive patients [13] . Additionally, patients who were cytology-negative, but CEA mRNA-positive, had signifi cantly poorer overall survival and diseasefree survival compared with CEA mRNA-negative patients [10] .
Other tumor markers have been studied in peritoneal washings of gastric cancer patients. When RT-PCR for CK20 mRNA, with 63% sensitivity and 91% specifi city rates, was combined with CEA mRNA, multivariate analysis identifi ed the presence of both markers as a signifi cant independent prognostic determinant [11] . Survivin is a protein, which, by RT-PCR, has a 66% sensitivity and 86% specifi city [14] . Additionally, MUC2 has a specifi city of 91% to 100% when used with other tumor markers [15] . The use of multiple tumor markers may optimize our ability to detect submicroscopic metastatic disease with a high degree of sensitivity and specifi city.
The purpose of this study was to investigate the ability of a quantitative RT-PCR assay to detect mRNA of tumor markers overly expressed in peritoneal washings of patients undergoing laparoscopy for gastric cancer, to defi ne the parameters to optimize RT-PCR, and to estimate the sensitivity, specifi city, and false-positive and false-negative rates of peritoneal cancer cell detection by quantitative RT-PCR when compared to cytology as the gold standard.
Methods

Patients
From March to August 2006, peritoneal washings were obtained prospectively from 34 consecutive patients with gastric adenocarcinoma undergoing diagnostic laparoscopy for staging at Memorial Sloan-Kettering Cancer Center (MSKCC). Patients eligible for this pilot study were more than 18 years of age and presented to the Surgical Services at MSKCC with histologically confi rmed gastric adenocarcinoma. Patients found to be potential candidates for surgical treatment based on history, physical examination, and conventional crosssectional body imaging were scheduled for laparoscopy. Patients were identifi ed preoperatively, offered participation, and required to provide informed consent.
In addition, peritoneal washings were obtained from 6 patients undergoing laparoscopy for benign conditions (e.g., gallstones, hernia, and prophylactic risk-reducing bilateral salpingoophorectomy). These negative control research subjects were identifi ed preoperatively by a member of the patient's treatment team at MSKCC. This study was conducted after MSKCC Institutional Review Board approval was gained.
Cancer cell lines
Established cell lines (BxPC3, HT-29) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Gastric cell line OCUM was generously donated by Osaka City University Graduate School of Medicine (Osaka, Japan). BxPC3 is a moderately differentiated pancreas cancer known to express MUC2 [16] . HT-29 is a colon cancer line which expresses CK20 [17] and survivin [18] . These cell lines were used as positive cancer controls for the RT-PCR assay. Cells were cultured as recommended and incubated at 37 °C with 5% CO 2 . RNA was isolated using the RNeasy Mini-Kit (Qiagen; Valencia, CA, USA) as described previously [19] . RT-PCR was performed with available RNA (≤2 μg) in a 100-μl reaction using random hexamer priming and TaqMan Reverse Transcription Reagents (Applied Biosystems; Foster City, CA, USA) on a Thermo Hybrid thermocycler (Waltham, MA, USA).
Laparoscopic evaluation
Patients underwent diagnostic laparoscopy in the standard fashion under general anesthesia as described previously [19] . Normal saline was introduced into the right upper abdomen, left upper abdomen, and pelvis and aspirated after gentle agitation but before manipulation of the primary or metastatic tumor. In all, three samples -from the right upper abdomen, left upper abdomen, and pelvis -were collected and divided into two parts: 30 ml from each sample was sent to the pathology department for cytologic examination with conventional Papanicolaou staining. Additionally, 50 ml was collected into a specimen cup and transported on ice to the laboratory for RNA isolation. During the laparoscopic examination, any visibly suspicious lesions were biopsied and sent for frozen section.
Cytologic evaluation
After retrieval, cytologic specimens were placed in Cytolyte fi xative (Cytyc, Marlborough, MA, USA) and submitted to the cytology laboratory for evaluation. After centrifugation for 10 min, the resulting cellular pellet underwent PreservCyte (Cytyc) fi xation. Using the Thin Prep procedure, two slide preparations were made. The fi rst was stained with a modifi ed hematoxylin and eosin preparation and the second using the Papanicolaou method.
RNA isolation
Each of three peritoneal wash samples per patient was centrifuged at 800 rpm for 5 min at 4 °C. From each sample, 10 ml of supernatant was removed for storage. The remaining specimens were centrifuged again at 800 rpm for 5 min at 4 °C. The three remaining pellets were combined and resuspended in 1 ml of supernatant and centrifuged at 8000 g for 5 min at 4 °C. The pellet was processed according to the RNeasy Mini-Kit (Qiagen) as described by the manufacturer and described previously [19] .
Real-time quantitative reverse transcriptase PCR (RT-PCR)
Reverse transcription was performed using the TaqMan Universal Reverse Transcriptase Master Mix (Applied Biosystems). First, the amount of RNA isolated from the washings was assessed using spectrophotometry. While each reverse transcriptase reaction requires 1.5 to 2 μg of RNA for optimal cDNA creation, most of these predominantly paucicellular specimens had less than 0.1 μg/μl of RNA. Therefore, we used the maximum volume of 38.5 μl of RNA from each peritoneal wash sample which was amplifi ed in a 100-μl reaction containing 1 uM of each primer, 20 μl of deoxynucleotide triphosphate, 25 mM MgCl 2 , 10 × Taq Buffer, random hexamers, RNAse inhibitor, and 2.5 μl Multiscribe Reverse Transcriptase (Applied Biosystems). The samples were transferred to the Thermo Hybrid thermocycler at 25 °C for 10 min, 48 °C for 30 min, and 95 °C for 5 min. The cDNA samples were stored at −20 °C.
TaqMan Assays-on-Demand Gene Expression Assay primers for carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), survivin, and MUC2 mRNA, as well as 18s rRNA were purchased from Applied Biosystems. Real-time quantitative RT-PCR was performed using the ABI-PRISM 7900 HT Sequence Detection System (Applied Biosystems). DNA was amplifi ed in a 20-μl reaction containing 1 μM of the appropriate primer, 2 μl cDNA, and TaqMan Gene Expression Master Mix including AmpliTaq Gold Polymerase. Each PCR reaction was subjected to initial setup of 30 min at 48 °C, 10 min at 95 °C, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. Each sample was assayed in triplicate with positive PCR controls, which were the cell lines that overexpressed these tumor markers. The endogenous control gene, 18s rRNA, was used to confi rm the presence of mRNA in the peritoneal wash samples.
Statistical analysis
Patient data, including clinical characteristics and pathologic fi ndings, were recorded and entered into a prospective database. Data for analysis included patient demographics, tumor pathologic characteristics, status of peritoneal cytology, and status of peritoneal tumor markers. The optimal threshold for cycle amplifi cation was chosen using a receiver operating characteristic (ROC) curve [20] and previously described [19] . The ROC curve is constructed by plotting sensitivity and specifi city pairs for tumor marker amplifi cation cycles, resulting from varying the cutoff values over the range of results. The sensitivity and specifi city of the tumor markers were estimated by using cytology as the gold standard, incorporating the information from negative controls as well as patients with malignancies. The "true positives" were defi ned as the patients who were found to have peritoneal metastases based on positive cytology or peritoneal metastases. Positive predictive value (PPV) and negative predictive value (NPV) of each marker were also computed. In addition, markers and their combinations were evaluated on the basis of their distance, or deviance, from the ideal marker (i.e., an ideal marker is 100% sensitive and specifi c).
Results
Patient demographics
From March through August 2006, 40 patients underwent laparoscopy and were entered into this pilot study; 34 patients had gastric cancer, and 6 had benign pathology. Patient demographic and clinicopathologic factors are shown in Tables 1-3 . The median age of the cancer patients was 66 years (range, 40-81 years; Table 1 ). Fourteen patients (41%) from the gastric cancer group were female. Within the gastric cancer group, 56% of patients (n = 19) underwent laparoscopy with biopsy while 44% underwent resection (distal subtotal gastrectomy, n = 12; total gastrectomy, n = 3).
Median age of the benign patients was 51 years (range, 41-68 years; Table 1 ); 83% of the benign patients were female. Within the benign group, four patients underwent risk-reducing bilateral salpingooophorectomy, while the others underwent laparoscopic cholecystectomy or laparoscopic ventral hernia repair.
Among the gastric cancer patients, the tumor was located in the antrum in 47% (n = 16) ( Table 2 ). Table 3 ). Positive cytology was identifi ed in 4 patients. Stages of their disease were stage II (n = 1), stage III (n = 1), and stage IV (n = 2). One patient with biopsy-proven peritoneal metastasis had negative cytology.
Cytology
The sensitivity and specifi city of cytology to detect peritoneal disease in this cohort was 67% and 95%, respectively. The PPV was 0.50 and NPV, 0.97. There were no cytology-positive patients in the benign patient group.
Primer optimization and positive controls
A total of four genes, CEA, CK20, survivin, and MUC2 were tested for expression in the cancer cell lines (Table  4) . CEA and CK20 mRNA transcripts amplifi ed at PCR cycle 22 in the OCUM and HT-29 cell lines, respectively. Survivin amplifi ed in the HT-29 cell line at cycle 25 while MUC2 amplifi ed in the BxPC3 cancer cell line at cycle 27. For each primer and cell line combination, the slopes of the PCR amplifi cation ranged from −3.1 to −3.9.
Expression of mRNA transcripts
All 34 gastric cancer patients had amplifi able RNA, as detected by the amplifi cation of the ribosomal 18s subunit within 20 cycles.
ROC curve analysis was performed for tumor marker mRNA expression using data from all patients evaluated. Sensitivities and specifi cities were calculated based on the diagnosis of positive cytology made at laparoscopy. The point on the ROC curve that was closest to the ideal marker was achieved by using 35 cycles as the threshold (Fig. 1) . Therefore, a tumor marker was deemed positive if 18s rRNA was amplifi ed and if there was tumor marker cycle amplifi cation within 35 cycles. Each potential tumor marker was evaluated separately.
Real-time RT-PCR using the TaqMan Assays-onDemand Gene Expression Assay allowed detection of CEA mRNA transcripts in eight patients within 35 cycles of amplifi cation ( Table 5 ). All of the patients with positive cytology had detectable levels of CEA. In addition, CEA mRNA was detected in four other patients, including the patient with peritoneal metastasis and negative cytology. CK20 mRNA transcripts were expressed in three patients within 35 cycles of RT-PCR with a sensitivity of 60% and specifi city of 94%. The deviance of CK20 from the ideal marker was 0.41.
Survivin mRNA transcripts were expressed in fi ve patients within 35 cycles of RT-PCR with a sensitivity and specifi city of 100% and 74%, respectively. The deviance of survivin from the ideal marker was 0.31.
MUC2 mRNA transcripts were expressed in two patients within 35 cycles of RT-PCR with a sensitivity of 40% and specifi city of 100%. The deviance of MUC2 from the ideal marker was 0.33.
Among the four tumor markers, CEA had the best profi le of sensitivity (100%), specifi city (91%), PPV (63%), and NPV 100% ( Table 5 ). The deviance from the ideal markerwas 0.13.
After each tumor marker was assessed individually, combinations of mRNA expression were analyzed for sensitivity, specifi city, PPV, NPV, and deviance (Table  5) . Combinations of CEA+CK20, CEA+MUC2, and CEA+CK20+MUC2 had deviances of 0.13, 0.15, and 0.15, respectively. Overall, 15 patients had at least one marker positive by RT-PCR (Table 3) . Eleven patients from stages IA through IV were cytology-negative but RT-PCRpositive, and they comprised the group of "falsepositives" with regard to RT-PCR when compared to the gold standard of cytology (Table 5 ). For the "falsepositive" gastric cancer patients, 3 patients expressed CEA mRNA transcripts; 9 patients were survivinpositive. CK20 and MUC2 mRNA transcripts were expressed in 2 and none of the "false-positive" gastric cancer patients, respectively.
Among the benign group which served as our negative controls, no patients were positive by RT-PCR for any of the four tumor markers.
Discussion
We have demonstrated that real-time RT-PCR can detect mRNA of tumor markers CEA, CK20, survivin, and MUC2 in peritoneal washings of patients undergoing laparoscopy for gastric cancer. Additionally, this pilot study defi ned the sensitivity, specifi city, and falsepositive and false-negative rates of RT-PCR for the four tumor markers when compared to the gold standard, cytology. Moreover, these four tumor markers were evaluated separately and in combination. CEA alone had a sensitivity of 100%, a specifi city of 91%, and a deviance of 0.13 from the ideal tumor marker. These fi ndings are comparable to previous Japanese reports [13] . As CEA alone had the smallest deviance, detection of CK20, survivin, and MUC2 in combination with CEA did not appear to provide additional benefi t.
The most frequent site of treatment failure following R0 resection for gastric cancer is the peritoneum [2, 3] , with a mean time to recurrence of 18 months [2] . To date, there are no effective therapies for peritoneal carcinomatosis, although there are randomized trials of intraperitoneal chemotherapy [21] . Therefore, detection of peritoneal disease prior to R0 resection is important for optimal treatment planning. Diagnostic laparoscopy with peritoneal washings and cytologic examination, accompanied by immunohistochemical staining with antibodies, has improved the sensitivity of detecting intraperitoneally shed tumor cells and predicting the risk of recurrent disease [3, 5, 6] . A close association between positive cytology and low survival rate has been demonstrated [5, 7, 22, 23] . Nevertheless, intraperitoneal recurrence has been observed even in patients with negative cytology [8] , suggesting a lack of sensitivity of conventional cytologic examination.
Reverse transcriptase-PCR (RT-PCR) has been used to identify the presence of CEA [9, 10] and CK20 mRNA, the two most commonly studied markers, in patients with submucosal, muscularis propria, and subserosal gastric cancers in several Japanese studies [11, 12] . One report, by Kodera et al. [13] , demonstrated that the survival of CEA mRNA-positive patients was poor and approached that of cytology-positive patients; recurrence was frequent among CEA mRNA-positive patients but rare for CEA mRNA-negative patients. Another report recently demonstrated that CEA positivity was an independent risk factor for cancer death and peritoneal recurrence after 5 years of follow up [24] ; however, that study did not segregate out the incremental value of RT-PCR by analyzing cytology (−)/PCR (+) patients separately.
Analysis of multiple tumor markers may improve our ability to detect intraperitoneal submicroscopic metastatic disease with a high degree of sensitivity and specifi city. RT-PCR for CK20 mRNA in our study had sensitivity and specifi city rates of 60% and 94%, respectively, rates which are comparable to previous studies [11] . When used with CEA, multivariate analysis has identifi ed the presence of both markers as a signifi cant independent prognostic determinant [11] . Our pilot study, however, did not demonstrate any benefi t of additional markers, CK20, survivin, or MUC2 over CEA mRNA. In contrast to our fi ndings, Mori et al. [25] recently showed that an RT-PCR-based microarray or immunocytochemical cytology including antibodies to CK20 and MUC2 had specifi city and sensitivity rates that were better than conventional cytology.
While CEA had high sensitivity and specifi city rates in our study, CK20, survivin, and MUC2 RT-PCR contributed to a large number of "false-positive" patients. Out of the 34 patients with gastric cancer, 15 patients had at least one marker positive by RT-PCR, 4 of whom were cytology (+)/RT-PCR (+), and 11 of whom were cytology (−)/RT-PCR (+). Nineteen patients were cytology (−)/RT-PCR (−). When we looked at the stages of disease, cytology status, and RT-PCR results, we identifi ed 11 patients from all stages who could be considered to be false-positives. Therefore, if RT-PCR is truly identifying subclinical peritoneal disease, it potentially quadruples the number of cytology (+) patients among all gastric cancer patients. Moreover, when we looked at the 31 patients with stage I through III disease, 2 patients were cytology (+)/RT-PCR (+) and 17 patients were cytology (−)/RT-PCR (−). Therefore, we identifi ed 10 patients, or a yield of 35%, who would be considered operative candidates after conventional cytology who are "false-positives". This underscores the potential importance of this technique in resectable patients. Discordance with negative cytology results may indicate that the tumor markers may increase the sensitivity of detection of disseminated disease in the peritoneal cavity, and this group of patients may represent an important population for study. The clinical signifi cance of these "false-positives" will be elucidated by long-term follow up and analysis of recurrence and survival, as has been demonstrated with CEA mRNA [24] .
Limitations of this pilot study included the small sample size and the logistical challenges of transporting the specimen from the patient to the laboratory within 1 h. Transport time was minimized by improved communication with the operating room staff and laboratory personnel. Another important limitation was the inability to quantify the RNA with two separate spectrophotometers before converting the RNA to cDNA. From specimens that did undergo spectrophotometry, the concentrations of mRNA were roughly less than 0.1 μg/μl. Two microliters of the RNA was used for reverse transcription, and 2 μl of the cDNA template was used in the PCR reaction. The presence of mRNA was confi rmed by amplifi cation of the 18s ribosomal subunit. In addition, the presence of tumor marker RNA was assessed by amplifi cation of signal within 35 cycles of the PCR reaction. Although specimens may have amplifi ed mRNA at various cycles of the PCR reaction, we could not quantify the tumor marker mRNA, because each sample did not begin with equal concentrations of mRNA. With the conclusion of this pilot study, we have begun to quantify mRNA with the use of a Nanodrop ND-1000 spectrophotometer (Wilmington, DE, USA). Additionally, there are benign causes for elevated CEA: smoking [26] , infl ammatory conditions including infections [27] , infl ammatory bowel disease [28] , hypothyroidism [29] , and pancreatitis and cirrhosis [30] . Levels can be raised transiently with radiation therapy [31] . Finally, assay variability can be a serious problem, and standardization for the volume of lavage fl uid used and the RT-PCR technique will be necessary if this method becomes widely practiced.
This pilot study is the fi rst American study to confi rm that real-time RT-PCR can detect mRNA of tumor markers overly expressed in peritoneal washings of patients undergoing laparoscopy for gastric cancer. Currently, our group is conducting a prospective, longitudinal study of 200 patients in order to defi ne the predictors and clinical signifi cance of a positive RT-PCR result, with particular attention to CEA and CK20. An answer of clinical signifi cance may not be fully available until adequate follow up of at least 2 years is obtained. Of interest will be the RT-PCR (+)/ cytology (−) patient undergoing curative resection. If a positive RT-PCR assay can identify a patient population at very high risk for early recurrence and death, this will clearly improve our therapeutic approach to patients with gastric cancer, as those patients may be unlikely to derive any meaningful benefi t from resection. At the same time, however, there will invariably be a small number of RT-PCR-positive patients who may be cured. Whether this is due to the limitation of RT-PCR or the fact that a very small number of cells may be destroyed immunologically is unknown. Applying this diagnostic technique to staging laparoscopy could undoubtedly be informative, but avoiding surgery for all of the cytology (−), RT-PCR (+) patients could deprive this select population of the chances of cure, although a recent study at MSKCC, in which highly selected patients who had positive peritoneal cytology as their only evidence of metastatic disease received neoadjuvant chemotherapy and eventually underwent surgical resection with therapeutic intent, showed maintenance of a poor prognosis [23] . Our longitudinal study may provide some insight into improving the specifi city of the RT-PCR examination. Nevertheless, the cost of conducting RT-PCR in these patients may provide the benefi t of preventing the potential morbidity, operative mortality, subsequent decrease in quality of life, and additional costs that may result from an operation that will not result in a curative resection. Ultimately, this would then result in improved selection of patients for operative management, reduction in operative resection and morbidity in patients who will have poor survival, and establishment of the routine use of laparoscopy, cytology, and mRNA of tumor markers as part of the preoperative workup.
Conclusion
RT-PCR using a panel of tumor markers, including CEA, was comparable to cytology in terms of sensitivity, specifi city, PPV, and NPV. The clinical signifi cance of "false-positive" overexpression of CEA, CK20, or survivin in patients with negative cytology and no clinical evidence of peritoneal metastatic disease remains to be defi ned. RT-PCR could represent a more sensitive method than cytology for detection of subclinical peritoneal tumor dissemination; this may be useful in improving the selection of patients for operative management and clinical trials.
